Longeveron Inc. develops regenerative cellular therapies centered on laromestrocel, also known as Lomecel-B, a proprietary allogeneic investigational cell therapy. The company’s clinical programs address hypoplastic left heart syndrome, Alzheimer’s disease, pediatric dilated cardiomyopathy, and aging-related frailty.
Recurring news for LGVN covers clinical-trial safety reviews, FDA interactions and designations, intellectual-property updates for mesenchymal stem cell methods, financial results, private placements, and Nasdaq-related corporate matters. Updates often focus on the ELPIS II HLHS program, laromestrocel regulatory strategy, and financing used to support clinical development.
Longeveron Inc. (NASDAQ: LGVN) announced the resignation of CEO Geoff Green, effective June 1, 2022. K. Chris Min, M.D., Ph.D., the current Chief Medical Officer, will serve as Interim CEO while a nationwide search for a permanent successor takes place. Under Green's leadership, Longeveron progressed significantly, advancing their Lomecel-B therapy into clinical trials. The company specializes in cellular therapies targeting aging-related and life-threatening conditions and is pursuing Phase 1 and 2 trials for multiple indications including Alzheimer’s disease and frailty.
Longeveron Inc. (NASDAQ: LGVN) will release its first quarter 2022 financial results on May 13, 2022, before the U.S. market opens. The management will host a conference call at 8:30 a.m. EST on the same day to discuss the results and provide corporate updates. Longeveron is focused on developing cellular therapies for aging-related and life-threatening conditions. Its lead product, Lomecel-B, is currently in Phase 1 and 2 trials addressing multiple serious conditions. For more, visit longeveron.com.
Longeveron Inc. (NASDAQ: LGVN) announces participation in key events showcasing its commitment to developing cell therapeutics for aging-related diseases. Key presentations include: April 20 - Kevin N. Ramdas discusses Lomecel-B clinical trial results at ICFSR, Boston. April 21 - Anthony Oliva presents on cognitive frailty. April 25 - Ramdas presents at the Latinos & Alzheimer’s Symposium. April 26 - Joshua Hare presents on aging and frailty at Longevity Leaders World Congress, London. The Company aims to advance its therapies into Phase 3 trials for conditions like Alzheimer's and Aging Frailty.
Longeveron Inc. (LGVN) announced a new Cooperative Research and Development Agreement (CRADA) with the U.S. Department of Veterans Affairs (VA) to add a Miami VA clinical site to its Phase 2 Alzheimer’s Disease trial. This collaboration marks the third CRADA with the VA, which also includes studies on aging frailty and Covid-19. The Phase 2 trial, named CLEAR MIND, will explore the safety and efficacy of Lomecel-B in treating mild Alzheimer’s, enrolling 48 patients. Recent peer-reviewed data indicated that Lomecel-B shows promise in slowing cognitive decline and improving quality of life.
Longeveron Inc. (NASDAQ: LGVN) has appointed Dr. K. Chris Min as Chief Medical Officer, effective April 4, 2022. Dr. Min will oversee global clinical development and regulatory strategy, particularly focusing on advancing Lomecel-B through pivotal trials. He brings over a decade of industry experience, including roles at Enterin and Cerevel Therapeutics. The company aims to progress Lomecel-B's development for conditions like Alzheimer's and Hypoplastic Left Heart Syndrome, with clinical trials expanding to Asia.
Longeveron Inc. (NASDAQ: LGVN) announced positive results from a Phase 1 trial of Lomecel-B for Alzheimer's disease, published in Alzheimer’s & Dementia. The study met its primary safety endpoint, showing that Lomecel-B was well tolerated, with no serious side effects observed. Preliminary findings suggest Lomecel-B may slow cognitive decline and improve patient quality of life. A Phase 2 trial has commenced, exploring single vs. multiple doses. The study indicates a potential for Lomecel-B to address multiple Alzheimer’s pathology features, as highlighted by encouraging changes in cognitive and brain health assessments.
Longeveron, a clinical-stage biotechnology company, presented at the Second Euro-Geroscience Conference on March 24-25, 2022, focusing on cellular therapies for aging-related conditions. Notable presentations included "Targeting Frailty with Stem Cells" and results for LOMECEL-B as a geroscience therapeutic candidate. Longeveron's lead product, derived from medicinal signaling cells, aims to treat conditions such as Aging Frailty and Alzheimer's. The company is advancing toward pivotal Phase 3 trials with regulatory approval in view.
Longeveron Inc. (NASDAQ: LGVN), a clinical-stage biotechnology company, announced that CEO Geoff Green will present at the Oppenheimer 32nd Annual Healthcare Conference on March 16, 2022. The virtual presentation is scheduled from 2:00 to 2:30 p.m. ET and will be accessible via Longeveron's website. The company specializes in cellular therapies targeting chronic, aging-related, and life-threatening conditions, focusing on its lead product, LOMECEL-B™. Longeveron is currently conducting Phase 1 and 2 trials for various conditions, including Alzheimer’s disease and Aging Frailty.
Longeveron (NASDAQ: LGVN) reported significant advancements in clinical trials for Lomecel-B, focusing on Hypoplastic Left Heart Syndrome, Alzheimer’s Disease, and COVID-related Acute Respiratory Distress Syndrome. The company received FDA designations for HLHS and raised $20.5 million in a private placement to support ongoing research. Despite a decline in revenue from $1.3 million in 2021 to $5.6 million in 2020, Longeveron expects sufficient cash to fund operations into 2024. Multiple data publications and a conference call to discuss results are scheduled for March 11, 2022.
Longeveron Inc. (NASDAQ: LGVN) plans to release its fourth quarter and year-end 2021 financial results on March 11, 2022, before U.S. markets open. A conference call will follow at 8:30 a.m. EST where management will discuss the results and provide a corporate update. The company focuses on cellular therapies for aging-related and life-threatening conditions, with its lead product LOMECEL-B undergoing Phase 1 and 2 trials for indications like Alzheimer’s disease and Aging Frailty.